A phase I trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan.
CONCLUSIONS: We report the first study of chemo-priming with epigenetic therapy in GI cancers. Guadecitabine 45 mg/m2 and irinotecan 125mg/m2 with GFS was safe and tolerable in mCRC patients, with early indication of benefit. These data have provided the basis for an ongoing phase II randomized, multicenter trial.
PMID: 30097434 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Lee V, Wang JS, Zahurak ML, Gootjes EC, Verheul HMW, Parkinson RM, Kerner Z, Sharma A, Rosner GL, De Jesus-Acosta A, Laheru DA, Le DT, Oganesian A, Lilly-Foreman E, Brown T, Jones PA, Baylin SB, Ahuja N, Azad NA Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | Genetics | Parkinson's Disease | Study | Toxicology